Elisabetta Patorno (Ajinkya Pawar)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 47

Top Topics

Glycemic Control

Clinical Practice

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

Journal of general internal medicine

Endocrinology, diabetes & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Jennifer J Yland, Krista F Huybrechts, Amelia K Wesselink, Loreen Straub, Yu-Han Chiu, Ellen W Seely, Elisabetta Patorno, Brian T Bateman, Helen Mogun, Lauren A Wise, Sonia Hernández-Díaz
Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus. Diabetes care (2024)
Phyo Than Htoo, Helen Tesfaye, Sebastian G Schneeweiss, Deborah J Wexler, Brendan M Everett, Robert J Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M Paik, Elisabetta Patorno
Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia (2024)
Helen Tesfaye, Katherine M Wang, Luke E Zabotka, Deborah J Wexler, Niklas Schmedt, Lisette Koeneman, Leo Seman, Julie M Paik, Elisabetta Patorno
Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study. Journal of general internal medicine 39 (10) (2024)
Helen Tesfaye, Katherine M Wang, Luke E Zabotka, Deborah J Wexler, Niklas Schmedt, Lisette Koeneman, Leo Seman, Julie M Paik, Elisabetta Patorno
Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study. Journal of general internal medicine (2024)
Helen Tesfaye, Katherine M Wang, Luke E Zabotka, Deborah J Wexler, Niklas Schmedt, Lisette Koeneman, Leo Seman, Julie M Paik, Elisabetta Patorno
Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study. Journal of general internal medicine 39 (10) (2024)
Edouard L Fu, Deborah J Wexler, Sara J Cromer, Katsiaryna Bykov, Julie M Paik, Elisabetta Patorno
SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ (Clinical research ed.) 385 (2024)
Jennifer J Yland, Krista F Huybrechts, Amelia K Wesselink, Loreen Straub, Yu-Han Chiu, Ellen W Seely, Elisabetta Patorno, Brian T Bateman, Helen Mogun, Lauren A Wise, Sonia Hernández-Díaz
Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus. Diabetes care 47 (9) (2024)
Phyo Than Htoo, Helen Tesfaye, Sebastian G Schneeweiss, Deborah J Wexler, Brendan M Everett, Robert J Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M Paik, Elisabetta Patorno
Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia 67 (7) (2024)
Jennifer J Yland, Krista F Huybrechts, Amelia K Wesselink, Loreen Straub, Yu-Han Chiu, Ellen W Seely, Elisabetta Patorno, Brian T Bateman, Helen Mogun, Lauren A Wise, Sonia Hernández-Díaz
Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus. Diabetes care 47 (9) (2024)
Jennifer J Yland, Krista F Huybrechts, Amelia K Wesselink, Loreen Straub, Yu-Han Chiu, Ellen W Seely, Elisabetta Patorno, Brian T Bateman, Helen Mogun, Lauren A Wise, Sonia Hernández-Díaz
Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus. Diabetes care 47 (9) (2024)
Edouard L Fu, Deborah J Wexler, Sara J Cromer, Katsiaryna Bykov, Julie M Paik, Elisabetta Patorno
SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ (Clinical research ed.) 385 (2024)
Edouard L Fu, Deborah J Wexler, Sara J Cromer, Katsiaryna Bykov, Julie M Paik, Elisabetta Patorno
SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ (Clinical research ed.) 385 (2024)
Helen Tesfaye, Katherine M Wang, Luke E Zabotka, Deborah J Wexler, Niklas Schmedt, Lisette Koeneman, Leo Seman, Julie M Paik, Elisabetta Patorno
Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study. Journal of general internal medicine 39 (10) (2024)
Seoyoung C Kim, Sebastian Schneeweiss, Robert J Glynn, Deborah J Wexler, Samy Suissa, Julie M Paik, Elisabetta Patorno
Bariatric surgery and all-cause mortality: A methodological review of studies using a non-surgical comparator. Diabetes, obesity & metabolism (2024)
Tracey G Simon, Deborah J Wexler, Sebastian Schneeweiss, Elisabetta Patorno
Antidiabetes Medication Initiation Trends in U.S. Adults with Cirrhosis and Type 2 Diabetes: A Nationwide Study. Diabetes, obesity & metabolism (2023)
Carolyn E Cesta, Sonia Hernandez-Diaz, Krista F Huybrechts, Brian T Bateman, Seanna Vine, Ellen W Seely, Elisabetta Patorno
Achieving comparability in glycemic control between antidiabetic treatment strategies in pregnancy when using real world data. Pharmacoepidemiology and drug safety (2023)
Alexander Kutz, Dae Hyun Kim, Deborah J Wexler, Jun Liu, Sebastian Schneeweiss, Robert J Glynn, Elisabetta Patorno
Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes care (2023)
Edouard L Fu, Elisabetta Patorno, Brendan M Everett, Muthiah Vaduganathan, Scott D Solomon, Raisa Levin, Sebastian G Schneeweiss, Rishi J Desai
Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. European heart journal (2023)
Devin Abrahami, Elvira D'Andrea, Hui Yin, Seoyoung C Kim, Julie M Paik, Deborah Wexler, Laurent Azoulay, Elisabetta Patorno
Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes, obesity & metabolism (2023)
HoJin Shin, Sebastian G Schneeweiss, Robert J Glynn, Elisabetta Patorno
Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes. Pharmacoepidemiology and drug safety 31 (5) (2022)
Sara Jane Cromer, Julie C Lauffenburger, Raisa Levin, Elisabetta Patorno
Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure. Diabetes care (2022)
HoJin Shin, Sebastian G Schneeweiss, Robert J Glynn, Elisabetta Patorno
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study. Annals of internal medicine 175 (7) (2022)
Devin Abrahami, Helen Tesfaye, Hui Yin, Seanna Vine, Blánaid Hicks, Oriana H Y Yu, Lysanne Campeau, Robert W Platt, Sebastian Schneeweiss, Elisabetta Patorno, Laurent Azoulay
Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes care 45 (12) (2022)
Chelsea E Hawley, Julie C Lauffenburger, Julie M Paik, Deborah J Wexler, Seoyoung C Kim, Elisabetta Patorno
Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries. Diabetes care 45 (3) (2022)
Elisabetta Patorno, Elisabetta Patorno, Lily G Bessette, Dae H Kim, Chintan Dave, Chintan V Dave, Medha N Munshi, Sebastian Schneeweiss, Deborah J Wexler, Seoyoung C Kim
Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes care 44 (3) (2021)
Michael Fralick, Sebastian Schneeweiss, Donald A Redelmeier, Fahad Razak, Tara Gomes, Elisabetta Patorno
Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. Diabetes, obesity & metabolism 23 (10) (2021)
Elisabetta Patorno, Sebastian Schneeweiss, Shirley V Wang
Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes. Diabetes, obesity & metabolism (2021)
Samantha T Harris, Elisabetta Patorno, Min Zhuo, Seoyoung C Kim, Julie M Paik
Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study. Diabetes care (2021)
Seoyoung C Kim, Sebastian Schneeweiss, Antonios Douros, Kristian B Filion, Hui Yin, Elisabetta Patorno, Laurent Azoulay
The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. Diabetes, obesity & metabolism 23 (11) (2021)
Seoyoung C Kim, Sebastian Schneeweiss, Dong Wook Kim, Elisabetta Patorno
Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States. Diabetes, obesity & metabolism 23 (7) (2021)
Elisabetta Patorno, Sebastian Schneeweiss, Mary G George, Xin Tong, Jessica M Franklin, Ajinkya Pawar, Helen Mogun, Lidia M V R Moura, Lee H Schwamm
Linking the Paul Coverdell National Acute Stroke Program to commercial claims to establish a framework for real-world longitudinal stroke research. Stroke and vascular neurology (2021)
HoJin Shin, Sebastian Schneeweiss, Robert J Glynn, Elisabetta Patorno
Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes care 44 (8) (2021)
Elvira D'Andrea, Lydia Vinals, Elisabetta Patorno, Jessica M Franklin, Dimitri Bennett, Joan A Largent, Daniela C Moga, Hongbo Yuan, Xuerong Wen, Andrew R Zullo, Thomas P A Debray, Grammati Sarri
How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools. BMJ open 11 (3) (2021)
Elisabetta Patorno, Ajinkya Pawar, Deborah J Wexler, Robert J Glynn, Lily G Bessette, Julie M Paik, Mehdi Najafzadeh, Kimberly G Brodovicz, Anouk Déruaz-Luyet, Sebastian Schneeweiss
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes, obesity & metabolism (2021)
Mollie E Wood, Elisabetta Patorno, Krista F Huybrechts, Brian T Bateman, Kathryn J Gray, Ellen W Seely, Seanna Vine, Sonia Hernández-Díaz
The use of glucose-lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States. Endocrinology, diabetes & metabolism 5 (2) (2021)
Michael Fralick, Martin Kulldorff, Donald Redelmeier, Shirley V Wang, Seanna Vine, Sebastian G Schneeweiss, Elisabetta Patorno
A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes. Endocrinology, diabetes & metabolism 4 (3) (2021)
Seoyoung C Kim, Sebastian Schneeweiss, Kueiyu Joshua Lin, Gregory Brill, Seoyoung C Kim, Elisabetta Patorno
Validation of obesity-related diagnosis codes in claims data. Diabetes, obesity & metabolism 23 (12) (2021)
Grammati Sarri, Elisabetta Patorno, Hongbo Yuan, Jianfei Jeff Guo, Dimitri Bennett, Xuerong Wen, Andrew R Zullo, Joan Largent, Mary Panaccio, Mugdha Gokhale, Daniela Claudia Moga, M Sanni Ali, Thomas P A Debray
Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making. BMJ evidence-based medicine (2020)
Chintan V Dave, Sebastian Schneeweiss, Deborah J Wexler, Gregory Brill, Elisabetta Patorno
Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018. Diabetes care 43 (4) (2020)
Mario Luca Morieri, Hetal S Shah, Jennifer Sjaarda, Petra A Lenzini, Hannah Campbell, Allison A Motsinger-Reif, He Gao, Laura Lovato, Sabrina Prudente, Assunta Pandolfi, Marcus G Pezzolesi, Ronald J Sigal, Guillaume Paré, Santica M Marcovina, Daniel M Rotroff, Elisabetta Patorno, Luana Mercuri, Vincenzo Trischitta, Emily Y Chew, Peter Kraft, John B Buse, Michael J Wagner, Sharon Cresci, Ulagamadesan Venkatesan, Henry N Ginsberg, Josyf C Mychaleckyj, Alessandro Doria
PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. Diabetes 69 (4) (2020)
Elisabetta Patorno, Sonia Hernandez-Diaz, Krista F Huybrechts, Rishi J Desai, Jacqueline M Cohen, Helen Mogun, Brian T Bateman
Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS medicine 17 (9) (2020)
Elisabetta Patorno, Chandrasekar Gopalakrishnan, Kimberly G Brodovicz, Andrea Meyers, Dorothee B Bartels, Jun Liu, Martin Kulldorff, Sebastian Schneeweiss
Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care. Diabetes, obesity & metabolism 21 (8) (2019)
Katsiaryna Bykov, Mengdong He, Jessica M Franklin, Elizabeth M Garry, John D Seeger, Elisabetta Patorno
Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data. Diabetes, obesity & metabolism 21 (9) (2019)
Elisabetta Patorno, Mehdi Najafzadeh, Ajinkya Pawar, Jessica M Franklin, Anouk Déruaz-Luyet, Kimberly G Brodovicz, Adrian J Santiago Ortiz, Lily G Bessette, Martin Kulldorff, Sebastian Schneeweiss
The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. Endocrinology, diabetes & metabolism 3 (1) (2019)
Elisabetta Patorno, Sebastian Schneeweiss, Chandrasekar Gopalakrishnan, David Martin, Jessica M Franklin
Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride. Diabetes care 42 (12) (2019)
Kazuki Yoshida, Daniel H Solomon, Sebastien J-P A Haneuse, Seoyoung C Kim, Elisabetta Patorno, Sara K Tedeschi, Houchen Lyu, Sonia Hernández-Díaz, Robert J Glynn
A tool for empirical equipoise assessment in multigroup comparative effectiveness research. Pharmacoepidemiology and drug safety 28 (7) (2019)
Elisabetta Patorno, Chandrasekar Gopalakrishnan, Jessica M Franklin, Kimberly G Brodovicz, Elvira Masso-Gonzalez, Dorothee B Bartels, Jun Liu, Sebastian Schneeweiss
Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes, obesity & metabolism 20 (4) (2018)